title: The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
abstract: Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (p < 0.001). The median M30 value after chemotherapy was an important prognostic factor for both overall survival (OS) (p = 0.002) and progression-free survival (PFS) (p = 0.002). Stage and histopathological type were significant both for PFS and OS. Multivariate analysis showed that the median M30 value after chemotherapy was the only independent prognostic factor for PFS (p = 0.04, HR 5.4) and OS (p = 0.02, HR 11.49). Our results indicated that both serum M30 and M65 values increased after chemotherapy in patients with advanced NSCLC, and an elevated serum M30 value was an independent prognostic factor for both PFS and OS.
authors.affiliation: Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. basakoven@yahoo.com
authors.forename: Bala Basak Oven
authors.initials: BB
authors.lastname: Ustaalioglu
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Serif
authors.initials: S
authors.lastname: Ercan
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.forename: Asuman
authors.initials: A
authors.lastname: Orcun
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053538:Keratin-18 / Q000096:biosynthesis / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000096:biosynthesis / Q000097:blood*; D011379:Prognosis; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D053538:Keratin-18; C561463:M30 cytokeratin-18 peptide, human; C577325:M65 antigen, human; D010446:Peptide Fragments
references.citation: Toxicol Lett. 1992 Dec;64-65 Spec No:553-61
references.pmid: 1471208
references.citation: Int Immunopharmacol. 2010 Jul;10(7):719-22
references.pmid: 20362077
references.citation: Am J Pathol. 2009 Aug;175(2):808-16
references.pmid: 19628770
references.citation: Cancer Res. 2004 Mar 1;64(5):1751-6
references.pmid: 14996736
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):314-8
references.pmid: 14514374
references.citation: Br J Cancer. 2006 Jun 5;94(11):1592-8
references.pmid: 16685278
references.citation: Eur J Cancer. 2003 Apr;39(6):769-74
references.pmid: 12651202
references.citation: Neoplasia. 2008 Oct;10(10):1041-8
references.pmid: 18813353
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3198-206
references.pmid: 17545523
references.citation: Br J Cancer. 2010 Feb 2;102(3):577-82
references.pmid: 20051949
references.citation: Cancer Chemother Pharmacol. 2011 Aug;68(2):309-16
references.pmid: 20967544
references.citation: Cancer Invest. 2006 Nov;24(7):669-76
references.pmid: 17118776
references.citation: J Thorac Oncol. 2007 Aug;2(8):706-14
references.pmid: 17762336
references.citation: Radiol Oncol. 2011 Jun;45(2):116-22
references.pmid: 22933944
references.citation: BMC Cancer. 2009 Mar 23;9:88
references.pmid: 19302716
references.citation: J Natl Cancer Inst. 1999 Mar 17;91(6):523-8
references.pmid: 10088622
references.citation: Biomed Pharmacother. 2005 Oct;59 Suppl 2:S359-62
references.pmid: 16507409
references.citation: Cancer J. 2002 Mar-Apr;8(2):82-92
references.pmid: 11999952
references.citation: Lung Cancer. 2007 Jun;56(3):399-404
references.pmid: 17316892